Skip to main content
profile image
Selected Works of Walter J. Urba, MD, PhD
Article
Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma.
Journal of Clinical Oncology (2018)
  • Richard Bryan Bell, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Rebekka Duhen, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Rom S. Leidner, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Brendan D. Curti, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Carmen Ballesteros-Merino, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Brian Piening, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Brady Bernard, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Joanna Pucilowska, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Carlo Bruno Bifulco, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Bernard A. Fox, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Thomas Duhen, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • William L Redmond, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Yoshinobu Koguchi, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Allen Cheng, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Ashish A. Patel, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • George Morris, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Raina Tamakawa, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Mark W. Schuster, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Walter John Urba, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
  • Andrew D. Weinberg, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR;
Link
Disciplines
Publication Date
May 20, 2018
DOI
10.1200/jco.2018.36.15_suppl.6011
Citation Information
Richard Bryan Bell, Rebekka Duhen, Rom S. Leidner, Brendan D. Curti, et al.. "Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma." Journal of Clinical Oncology Vol. 36 (2018) p. 6011 - 6011
Available at: http://works.bepress.com/walter-urba/252/